GGrantIndex
← Search

Microparticulate Caspase-1 mediated Lung Injury.

$385,000R01FY2019HLNIH

Ohio State University, Columbus OH

Investigators

Linked publications & trials

Abstract

? DESCRIPTION (provided by applicant): Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are the most prevalent clinical syndromes associated with severe sepsis and are important causes of morbidity and mortality in United States with a mortality rate of 40%. Although much is known about the pathogenesis of cell injury and death in ALI/ARDS, there are several gaps in our knowledge; as a result of which there is currently no effective pharmacologic therapy. In this context, enzymes known as caspases are essential for completion of the apoptotic program. Phagocytes, in particular monocyte/macrophages, are recognized as major components of inflammatory and immunologic reactions in the lung and are rich reservoirs of caspases, especially caspase-1. The function of caspase-1 has recently been recognized to extend beyond the processing and activation of IL-1ß and IL-18 to include regulation of NF-kB and induction of apoptosis. The present project seeks to expand upon our recent observation that microparticulate caspase-1 can be released from mononuclear phagocytes to have distant effects on target cells. The present project seeks to investigate a novel hypothesis that links apoptotic enzyme, caspase-1, encapsulated in circulatory vesicles, to lung cell injury and apoptosis. The central hypothesis is that monocyte/macrophage caspase-1 released in target specific microparticles can promote lung cell apoptosis, enhancing lung injury. This project provides a much needed effort and framework to study the poorly understood mechanism of endothelial cell injury and vascular dysfunction in ARDS patients, to enhance our understanding of the molecular mechanisms underlying the cell injury and provide new therapeutic opportunities to halt the cell injury in ALI/ARDS patients. Therefore, to determine the specifics of this novel pathway, we propose the following specific aims: 1) To discover the detailed mechanisms by which monocyte derived extracellular caspase-1 injures lung vascular endothelial cells, 2) To characterize the forms of circulating caspase-1 present in the serum of critically ill patients and 3) To determine how extracellular caspase-1 is taken up by target cells. This project provides an opportunity to examine the role of caspase-1 in the complex biology of monocyte/endothelial cell interactions and apoptosis. Successful completion of this work will uncover critical components of microparticles and caspase-1 mediated inflammasome signaling, enhance our understanding of the molecular mechanisms underlying the cell injury and provide new therapeutic opportunities to halt the lung destruction in septic patients with ALI/ARDS.

View original record on NIH RePORTER →